

# John M Lachin

## List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/2316927/publications.pdf](https://exaly.com/author-pdf/2316927/publications.pdf)

Version: 2025-02-01

257

PR articles

50,266

PR citations

5763

77

PR h-index

1390

219

g-index

278

documents

59510

doc citations

5877

83

h-index

57411

citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes Risk Factors and Bone Microarchitecture as Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Adults With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , 2024, 47, 1548-1558.	6.2	10
2	Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial. <i>Diabetes Care</i> , 2024, 47, 562-570.	6.2	10
3	Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes. <i>Diabetes Care</i> , 2024, 47, 1559-1567.	6.2	10
4	Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes. <i>Diabetes</i> , 2024, 73, 823-833.	4.2	24
5	Epicardial and intra-thoracic adipose tissue and cardiovascular calcifications in type 1 diabetes (T1D) in epidemiology of diabetes Interventions and Complications (EDIC): A pilot study. <i>American Journal of Preventive Cardiology</i> , 2024, 18, 100650.	2.8	0
6	History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Complications Study: Studies That Changed the Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , 2024, 47, 1511-1517.	6.2	6
7	Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial. <i>Diabetes Care</i> , 2024, 47, 2155-2163.	6.2	7
8	Glycemia reduction in type 2 diabetes—Hypoglycemia outcomes: A randomized clinical trial. <i>PLoS ONE</i> , 2024, 19, e0309907.	2.3	2
9	Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2023, 46, 361-368.	6.2	17
10	Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2022;45:2445–2448. <i>Diabetes Care</i> , 2023, 46, e13-e13.	6.2	2
11	CKD Associates with Cognitive Decline in Middle-Aged and Older Adults with Long-Standing Type 1 Diabetes. <i>Kidney360</i> , 2023, 4, 1058-1071.	1.9	2
12	Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients. <i>Journal of Diabetes Investigation</i> , 2022, 13, 125-133.	2.7	42
13	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 585-593.	6.2	5
14	Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 659-665.	6.2	28
15	Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2405-e2416.	4.1	21
16	Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications. <i>American Journal of Cardiology</i> , 2022, 174, 158-165.	1.8	2
17	Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 509-518.	21.8	41
18	Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2022, 45, 1779-1787.	6.2	25

#	ARTICLE	IF	CITATIONS
19	Physical Function in Middle-aged and Older Adults With Type 1 Diabetes: Long-term Follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2022, 45, 2037-2045.	6.2	11
20	Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2022, 45, 2445-2448.	6.2	13
21	Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e2230710.	6.6	40
22	Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 2943-2949.	6.2	4
23	Refractive Error and Retinopathy Outcomes in Type 1 Diabetes. <i>Ophthalmology</i> , 2021, 128, 554-560.	7.8	13
24	Moderation of the effect of glycemia on the risk of cardiovascular disease in type 1 diabetes: The DCCT/EDIC study. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108591.	5.9	14
25	Association of Baseline Characteristics With Insulin Sensitivity and $\beta$ -Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , 2021, 44, 340-349.	6.2	19
26	OGTT Glucose Response Curves, Insulin Sensitivity, and $\beta$ -Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve $\beta$ -Cell Function. <i>Diabetes Care</i> , 2021, 44, 817-825.	6.2	40
27	Residual $\beta$ cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	10.6	73
28	Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2021, 44, 1309-1316.	6.2	8
29	Cost-efficient clinical studies with continuous time survival outcomes. <i>Statistics in Medicine</i> , 2021, 40, 3682-3694.	1.7	1
30	Association of glycemia with insulin sensitivity and $\beta$ -cell function in adults with early type 2 diabetes on metformin alone. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107912.	2.4	8
31	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1499-1505.	6.2	33
32	Hyperglucagonemia Does Not Explain the $\beta$ -Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. <i>Diabetes Care</i> , 2021, 44, 1961-1969.	6.2	18
33	Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 436-445.	21.8	113
34	Serum urate and cardiovascular events in the DCCT/EDIC study. <i>Scientific Reports</i> , 2021, 11, .	3.4	7
35	The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 2225-2230.	6.2	48
36	Mediators of the Improvement in Heart Failure Outcomes with Empagliflozin in the EMPA-REG OUTCOME Trial. <i>ESC Heart Failure</i> , 2021, 8, 4517-4527.	3.2	73

#	ARTICLE	IF	CITATIONS
37	Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. PLoS ONE, 2021, 16, e0257154.	2.3	16
38	Coronary Artery Disease Events and Carotid Intima-Media Thickness in Type 1 Diabetes in the DCCT/EDIC Cohort. Journal of the American Heart Association, 2021, 10, .	4.0	13
39	Closed testing of each group versus the others combined in a multiple group analysis. Clinical Trials, 2020, 17, 77-86.	1.8	3
40	Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatric Diabetes, 2020, 21, 1437-1446.	5.5	8
41	Worst-Rank Score Methods—A Nonparametric Approach to Informatively Missing Data. JAMA - Journal of the American Medical Association, 2020, 324, 1670.	16.6	6
42	DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. Nature Metabolism, 2020, 2, 744-762.	17.1	82
43	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. Diabetes Care, 2020, 43, 2478-2484.	6.2	24
44	Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes, 2020, 69, 2440-2445.	4.2	5
45	The minimum intensity of a mixed exposure that increases the risk of an outcome. Statistics in Medicine, 2020, 39, 4016-4024.	1.7	0
46	Nonparametric Statistical Analysis. JAMA - Journal of the American Medical Association, 2020, 323, 2080.	16.6	23
47	Models to Assess the Association of a Semiquantitative Exposure With Outcomes. American Journal of Epidemiology, 2020, 189, 1573-1582.	3.3	3
48	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291-299. Diabetes, 2020, 69, e7-e8.	4.2	3
49	Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes, 2020, 69, 1000-1010.	4.2	186
50	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2020, 43, 867-874.	6.2	82
51	Risk Factors for Hearing Impairment in Type 1 Diabetes. Endocrine Practice, 2019, 25, 1243-1254.	3.3	10
52	Closed testing using surrogate hypotheses with restricted alternatives. PLoS ONE, 2019, 14, e0219520.	2.3	3
53	Immune Complexes and the Risk of CVD in Type 1 Diabetes. Diabetes, 2019, 68, 1853-1860.	4.2	18
54	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 854-861.	4.2	47

#	ARTICLE	IF	CITATIONS
55	Association of Habitual Daily Physical Activity With Glucose Tolerance and $\beta$ -Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. <i>Diabetes Care</i> , 2019, 42, 1521-1529.	6.2	14
56	Lack of Durable Improvements in $\beta$ -Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1742-1751.	6.2	67
57	Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 1284-1289.	6.2	56
58	Risk Factors for Kidney Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 883-890.	6.2	116
59	Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 875-882.	6.2	172
60	The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1341-1349.	6.2	69
61	Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2019, 42, 657-664.	6.2	40
62	Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> 2019;42:657-664. <i>Diabetes Care</i> , 2019, 42, e137-e137.	6.2	1
63	Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes. <i>PLoS ONE</i> , 2019, 14, e0210367.	2.3	23
64	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 128-139.	21.8	322
65	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME <sup>®</sup> trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	2.2	227
66	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. <i>Diabetes Care</i> , 2018, 41, 596-603.	6.2	65
67	Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	4.0	9
68	Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. <i>Diabetes Care</i> 2017;40:655-662. <i>Diabetes Care</i> , 2018, 41, e64-e64.	6.2	3
69	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	18.1	413
70	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	6.2	623
71	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 1599-1601.	18.1	36
72	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. <i>Diabetes Care</i> , 2018, 41, 2495-2501.	6.2	39

#	ARTICLE	IF	CITATIONS
73	Impact of Insulin and Metformin Versus Metformin Alone on $\beta$ -Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1717-1725.	6.2	155
74	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. <i>Diabetes Care</i> , 2018, 41, 1696-1706.	6.2	153
75	The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC). <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 934-939.	2.4	15
76	Properties of composite time to first event versus joint marginal analyses of multiple outcomes. <i>Statistics in Medicine</i> , 2018, 37, 3918-3930.	1.7	6
77	What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 911-915.	2.4	36
78	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves $\beta$ -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , 2018, 41, 1917-1925.	6.2	166
79	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , 2018, 41, 1887-1894.	6.2	151
80	Optimal screening schedules for disease progression with application to diabetic retinopathy. <i>Biostatistics</i> , 2018, 19, 1-13.	2.1	16
81	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2017, 40, 777-783.	6.2	165
82	Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2017, 376, 1507-1516.	34.6	123
83	Refining Measurement of Hemoglobin A1c. <i>Clinical Chemistry</i> , 2017, 63, 1433-1435.	1.1	10
84	Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. <i>Diabetes Care</i> , 2017, 40, 1010-1016.	6.2	128
85	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	6.0	124
86	Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing $\beta$ -cell function in diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, .	4.9	9
87	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , 2017, 40, 793-799.	6.2	19
88	Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2017, 40, 405-411.	6.2	41
89	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> 2017;40:777-783. <i>Diabetes Care</i> , 2017, 40, e165-e166.	6.2	2
90	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. <i>Diabetes Care</i> , 2017, 40, 1763-1770.	6.2	66

#	ARTICLE	IF	CITATIONS
91	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	6.6	13
92	The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. <i>Diabetologia</i> , 2017, 60, 2084-2091.	7.6	73
93	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000461.	5.4	13
94	Pancreatic Safety of Sitagliptin in the TECOS Study. <i>Diabetes Care</i> , 2017, 40, 164-170.	6.2	53
95	Probabilistic measures of cost-effectiveness. <i>Statistics in Medicine</i> , 2016, 35, 3976-3986.	1.7	3
96	Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	4.0	21
97	Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. <i>European Heart Journal</i> , 2016, 37, 1526-1534.	2.2	871
98	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. <i>JAMA Cardiology</i> , 2016, 1, 126.	11.2	208
99	Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, .	7.5	200
100	Haptoglobin 2 <sup>nd</sup> genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1577-1584.	2.4	21
101	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1969-1977.	4.2	111
102	Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2016, 15, .	9.4	21
103	Fallacies of last observation carried forward analyses. <i>Clinical Trials</i> , 2016, 13, 161-168.	1.8	262
104	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	34.6	3,297
105	Large sample inference for a win ratio analysis of a composite outcome based on prioritized components. <i>Biostatistics</i> , 2016, 17, 178-187.	2.1	110
106	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 374, 1092-1094.	34.6	257
107	Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study. <i>PLoS ONE</i> , 2016, 11, e0159958.	2.3	15
108	Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, .	9.4	53

#	ARTICLE	IF	CITATIONS
109	Data sharing is desirable, but benefits should not be exaggerated. <i>BMJ</i> , The, 2015, , h5508.	0.2	1
110	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 232-242.	34.6	2,393
111	Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes. <i>Clinical Trials</i> , 2015, 12, 627-633.	1.8	29
112	Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 45.	16.6	404
113	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimpiride in Type 2 Diabetes (CAROLINA) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 582 Td (	2.7	1,078,431
114	Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2015, 372, 1722-1733.	34.6	101
115	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 2117-2128.	34.6	10,749
116	The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 108-114.	2.4	32
117	Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). <i>Diabetes</i> , 2015, 64, 989-998.	4.2	45
118	Skin Advanced Glycation End Products Glucosepane and Methylglyoxal Hydroimidazolone Are Independently Associated With Long-term Microvascular Complication Progression of Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 266-278.	4.2	129
119	Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC. <i>Diabetes</i> , 2015, 64, 631-642.	4.2	306
120	Applications of the Wei-Lachin Multivariate One-Sided Test for Multiple Outcomes on Possibly Different Scales. <i>PLoS ONE</i> , 2014, 9, e108784.	2.3	35
121	Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2014, 37, 39-43.	6.2	188
122	Methods for a longitudinal quantitative outcome with a multivariate Gaussian distribution multi-dimensionally censored by therapeutic intervention. <i>Statistics in Medicine</i> , 2014, 33, 1288-1306.	1.7	1
123	Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study. <i>Diabetes</i> , 2014, 63, 282-290.	4.2	204
124	Evaluating the Role of Epigenetic Histone Modifications in the Metabolic Memory of Type 1 Diabetes. <i>Diabetes</i> , 2014, 63, 1748-1762.	4.2	228
125	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 810-818.	0.4	44
126	Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial. <i>Diabetes</i> , 2014, 63, 739-748.	4.2	253

#	ARTICLE	IF	CITATIONS
127	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2342-2350.	0.4	84
128	Identifying Change Points in a Covariate Effect on Time-to-Event Analysis with Reduced Isotonic Regression. <i>PLoS ONE</i> , 2014, 9, e113948.	2.3	2
129	Power of the Mantel-Haenszel and other tests for discrete or grouped time-to-event data under a chained binomial model. <i>Statistics in Medicine</i> , 2013, 32, 220-229.	1.7	9
130	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 289-301.	2.7	134
131	Validity of Self-Report in Type 1 Diabetic Subjects for Laser Treatment of Retinopathy. <i>Ophthalmology</i> , 2013, 120, 2580-2586.	7.8	9
132	The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 141-149.	2.4	51
133	Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata. <i>Statistics in Medicine</i> , 2013, 32, 4413-4425.	1.7	16
134	Effects of Prior Intensive Versus Conventional Therapy and History of Glycemia on Cardiac Function in Type 1 Diabetes in the DCCT/EDIC. <i>Diabetes</i> , 2013, 62, 3561-3569.	4.2	43
135	Reminiscences of Jerry Cornfield. <i>Clinical Trials</i> , 2013, 10, 337-339.	1.8	0
136	Aortic Distensibility in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2380-2387.	6.2	23
137	Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 2013, 36, 2254-2261.	6.2	238
138	Haptoglobin Genotype and the Rate of Renal Function Decline in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes</i> , 2013, 62, 3218-3223.	4.2	38
139	Circulating Vitamin D Metabolites and Subclinical Atherosclerosis in Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2423-2429.	6.2	31
140	Fall in C-Peptide During First 2 Years From Diagnosis. <i>Diabetes</i> , 2012, 61, 2066-2073.	4.2	303
141	High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1416-1423.	0.8	39
142	Pilot Genome-Wide Association Search Identifies Potential Loci for Risk of Erectile Dysfunction in Type 1 Diabetes Using the DCCT/EDIC Study Cohort. <i>Journal of Urology</i> , 2012, 188, 514-520.	4.2	18
143	Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4780-4788.	4.1	58
144	Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes. <i>Journal of Urology</i> , 2011, 185, 1828-1834.	4.2	83



#	ARTICLE	IF	CITATIONS
163	Point: Intensive Glycemic Control and Mortality in ACCORD—A Chance Finding?. <i>Diabetes Care</i> , 2010, 33, 2719-2721.	6.2	18
164	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. <i>Diabetes Care</i> , 2010, 33, 1536-1543.	6.2	276
165	Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1235-1242.	4.2	54
166	Effect of Prior Intensive Insulin Treatment During the Diabetes Control and Complications Trial (DCCT) on Peripheral Neuropathy in Type 1 Diabetes During the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. <i>Diabetes Care</i> , 2010, 33, 1090-1096.	6.2	342
167	Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 134-142.	4.1	172
168	Association of diet with glycated hemoglobin during intensive treatment of type 1 diabetes in the Diabetes Control and Complications Trial. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 518-524.	4.7	140
169	Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes. <i>Diabetes</i> , 2009, 58, 2588-2595.	4.2	92
170	Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus. <i>Circulation</i> , 2009, 119, 2886-2893.	18.1	299
171	The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. <i>Pediatric Diabetes</i> , 2009, 10, 97-104.	5.5	181
172	Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function. <i>New England Journal of Medicine</i> , 2009, 361, 2143-2152.	34.6	1,011
173	Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model. <i>Statistics in Medicine</i> , 2008, 27, 2509-2523.	1.7	54
174	Type 1 Diabetes TrialNet—An International Collaborative Clinical Trials Network. <i>Annals of the New York Academy of Sciences</i> , 2008, 1150, 14-24.	4.0	103
175	Rosiglitazone-Associated Fractures in Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 845-851.	6.2	521
176	A Risk Score for Type 1 Diabetes Derived From Autoantibody-Positive Participants in the Diabetes Prevention Trial—Type 1. <i>Diabetes Care</i> , 2008, 31, 528-533.	6.2	101
177	Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of $\beta$ -Cell Function in Therapeutic Trials in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1966-1971.	6.2	276
178	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2008, 168, 1867.	8.1	110
179	Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes Mellitus. <i>JAMA Ophthalmology</i> , 2008, 126, 1707.	2.2	320
180	Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. <i>Diabetes</i> , 2007, 56, 1153-1159.	4.2	94

#	ARTICLE	IF	CITATIONS
181	A composite design for transition from a preliminary to a full-scale study. <i>Statistics in Medicine</i> , 2007, 26, 5014-5032.	1.7	3
182	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 2427-2443.	34.6	2,837
183	Operating characteristics of sample size re-estimation with futility stopping based on conditional power. <i>Statistics in Medicine</i> , 2006, 25, 3348-3365.	1.7	15
184	Parametric survival models for interval-censored data with time-dependent covariates. <i>Biostatistics</i> , 2006, 7, 599-614.	2.1	81
185	A review of methods for futility stopping based on conditional power. <i>Statistics in Medicine</i> , 2005, 24, 2747-2764.	1.7	207
186	Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2005, 353, 2643-2653.	34.6	4,660
187	Maximum information designs. <i>Clinical Trials</i> , 2005, 2, 453-464.	1.8	7
188	Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al.. <i>Diabetes Care</i> , 2005, 28, 233-233.	6.2	11
189	The Society for Clinical Trials supports United States legislation mandating trials registration. <i>Clinical Trials</i> , 2004, 1, 417-420.	1.8	7
190	The role of measurement reliability in clinical trials. <i>Clinical Trials</i> , 2004, 1, 553-566.	1.8	212
191	Achieving Weight and Activity Goals Among Diabetes Prevention Program Lifestyle Participants. <i>Obesity</i> , 2004, 12, 1426-1434.	4.1	488
192	Conflicts of interest in data monitoring of industry versus publicly financed clinical trials. <i>Statistics in Medicine</i> , 2004, 23, 1519-1521.	1.7	10
193	A tribute to Samuel W. Greenhouse. <i>Statistics in Medicine</i> , 2003, 22, 3267-3276.	1.7	3
194	Over-ruling a group sequential boundary? a stopping rule versus a guideline. <i>Statistics in Medicine</i> , 2003, 22, 3347-3355.	1.7	14
195	Group sequential large sample T <sup>2</sup> -like tests for multivariate observations. <i>Statistics in Medicine</i> , 2003, 22, 3357-3368.	1.7	1
196	Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2003, 348, 2294-2303.	34.6	782
197	Corrections for Bias in Maximum Likelihood Parameter Estimates Due to Nuisance Parameters. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2003, 32, 619-639.	1.3	3
198	Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. <i>New England Journal of Medicine</i> , 2002, 346, 393-403.	34.6	17,207

#	ARTICLE	IF	CITATIONS
199	Application of robust estimating equations to the analysis of quantitative longitudinal data. <i>Statistics in Medicine</i> , 2001, 20, 3411-3428.	1.7	12
200	Statistical Considerations in the Intent-to-Treat Principle. <i>Contemporary Clinical Trials</i> , 2000, 21, 167-189.	2.8	574
201	A Flexible Stochastic Curtailing Procedure for the Log-Rank Test. <i>Contemporary Clinical Trials</i> , 2000, 21, 428-439.	2.8	13
202	Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. <i>New England Journal of Medicine</i> , 2000, 342, 381-389.	34.6	1,524
203	Worst-Rank Score Analysis with Informatively Missing Observations in Clinical Trials. <i>Contemporary Clinical Trials</i> , 1999, 20, 408-422.	2.8	145
204	Link-Based Models for Survival Data with Interval and Continuous Time Censoring. <i>Biometrics</i> , 1997, 53, 1199.	1.6	40
205	GROUP SEQUENTIAL MONITORING OF DISTRIBUTION-FREE ANALYSES OF REPEATED MEASURES. <i>Statistics in Medicine</i> , 1997, 16, 653-668.	1.7	14
206	The Efficacy of Tolrestat in the Treatment of Diabetic Peripheral Neuropathy: A meta-analysis of individual patient data. <i>Diabetes Care</i> , 1996, 19, 1091-1096.	6.2	28
207	Distribution-Free Marginal Analysis of Repeated Measures. <i>Drug Information Journal</i> , 1996, 30, 1017-1028.	0.0	8
208	Martingales without tears. <i>Lifetime Data Analysis</i> , 1995, 1, 361-375.	0.8	4
209	Nonparametric test of stochastic ordering for multiple longitudinal measures. <i>Journal of Biopharmaceutical Statistics</i> , 1995, 5, 235-243.	1.4	3
210	Sequential Monitoring of Survival Data with the Wilcoxon Statistic. <i>Biometrics</i> , 1995, 51, 1175.	1.6	23
211	Natural history and course of acquired lactic acidosis in adults. <i>American Journal of Medicine</i> , 1994, 97, 47-54.	2.0	199
212	Use of spending functions for occasional or continuous monitoring of data in clinical trials. <i>Statistics in Medicine</i> , 1993, 12, 2219-2231.	1.7	25
213	The use of response-adaptive designs in clinical trials. <i>Contemporary Clinical Trials</i> , 1993, 14, 471-484.	2.8	96
214	A Controlled Clinical Trial of Dichloroacetate for Treatment of Lactic Acidosis in Adults. <i>New England Journal of Medicine</i> , 1992, 327, 1564-1569.	34.6	327
215	A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis. <i>New England Journal of Medicine</i> , 1992, 326, 1373-1379.	34.6	476
216	Group Sequential Distribution-Free Methods for the Analysis of Multivariate Observations. <i>Biometrics</i> , 1992, 48, 1033.	1.6	42

#	ARTICLE	IF	CITATIONS
217	Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. <i>Statistics in Medicine</i> , 1992, 11, 1151-1170.	1.7	108
218	Power and sample size evaluation for the mcnemar test with application to matched case-control studies. <i>Statistics in Medicine</i> , 1992, 11, 1239-1251.	1.7	60
219	Termination of a clinical trial with no treatment group difference: The Lupus Nephritis Collaborative Study. <i>Contemporary Clinical Trials</i> , 1992, 13, 62-79.	2.8	26
220	Implementation of Group Sequential Logrank Tests in a Maximum Duration Trial. <i>Biometrics</i> , 1990, 46, 759.	1.6	72
221	Permutation tests following restricted randomization procedures. <i>Contemporary Clinical Trials</i> , 1990, 11, 150-152.	2.8	0
222	Remembrances of Max Halperin. <i>Statistics in Medicine</i> , 1990, 9, 863-870.	1.7	2
223	Interim analyses with repeated measurements in a sequential clinical trial. <i>Biometrika</i> , 1990, 77, 359-364.	2.7	55
224	Estimators and Tests in the Analysis of Multiple Nonindependent 2 X 2 Tables with Partially Missing Observations. <i>Biometrics</i> , 1988, 44, 513.	1.6	22
225	Properties of randomization in clinical trials: Foreword. <i>Contemporary Clinical Trials</i> , 1988, 9, 287-288.	2.8	13
226	Statistical properties of randomization in clinical trials. <i>Contemporary Clinical Trials</i> , 1988, 9, 289-311.	2.8	195
227	Properties of simple randomization in clinical trials. <i>Contemporary Clinical Trials</i> , 1988, 9, 312-326.	2.8	158
228	Properties of permuted-block randomization in clinical trials. <i>Contemporary Clinical Trials</i> , 1988, 9, 327-344.	2.8	279
229	Properties of the urn randomization in clinical trials. <i>Contemporary Clinical Trials</i> , 1988, 9, 345-364.	2.8	295
230	Randomization in clinical trials: Conclusions and recommendations. <i>Contemporary Clinical Trials</i> , 1988, 9, 365-374.	2.8	245
231	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. <i>Journal of the American Statistical Association</i> , 1988, 83, 339-347.	3.4	124
232	Analysis of Recurrent Events: Nonparametric Methods for Random-Interval Count Data. <i>Journal of the American Statistical Association</i> , 1988, 83, 339.	3.4	29
233	External monitoring of a data coordinating center: Experience of the national cooperative gallstone study. <i>Contemporary Clinical Trials</i> , 1987, 8, 1-11.	2.8	14
234	Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification. <i>Biometrics</i> , 1986, 42, 507.	1.6	369

#	ARTICLE	IF	CITATIONS
235	Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. <i>Statistics in Medicine</i> , 1986, 5, 73-83.	1.7	37
236	Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations. <i>Journal of the American Statistical Association</i> , 1984, 79, 653-661.	3.4	279
237	Major issues in the organization and implementation of the national cooperative Gallstone Study (NCGS). <i>Contemporary Clinical Trials</i> , 1984, 5, 1-12.	2.8	3
238	Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations. <i>Journal of the American Statistical Association</i> , 1984, 79, 653.	3.4	64
239	Effects of dose relative to body weight in the national cooperative gallstone study: A fixed-dose trial. <i>Contemporary Clinical Trials</i> , 1983, 4, 125-131.	2.8	3
240	Central laboratory quality control in the national cooperative gallstone study. <i>Contemporary Clinical Trials</i> , 1983, 4, 101-123.	2.8	11
241	The National Cooperative Gallstone Study and current management of cholesterol cholelithiasis—Two views. <i>Gastroenterology</i> , 1983, 84, 644-648.	0.9	9
242	Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients With Cholelithiasis: the National Cooperative Gallstone Study. <i>Hepatology</i> , 1983, 3, 209-220.	10.1	32
243	National Cooperative Gallstone Study. <i>Gastroenterology</i> , 1982, 82, 638-646.	0.9	82
244	Pretreatment Biliary Lipid Composition in White Patients with Radiolucent Gallstones in the National Cooperative Gallstone Study. <i>Gastroenterology</i> , 1982, 83, 738-752.	0.9	109
245	A Prospective Morphologic Evaluation of Hepatic Toxicity of Chenodeoxycholic Acid in Patients With Cholelithiasis: the National Cooperative Gallstone Study. <i>Hepatology</i> , 1982, 2, 187S-201S.	10.1	52
246	Sequential Clinical Trials for Normal Variates Using Interval Composite Hypotheses. <i>Biometrics</i> , 1981, 37, 87.	1.6	12
247	Introduction to sample size determination and power analysis for clinical trials. <i>Contemporary Clinical Trials</i> , 1981, 2, 93-113.	2.8	953
248	Perceptions of the coordinating center. <i>Contemporary Clinical Trials</i> , 1980, 1, 125-126.	2.8	1
249	Sample Size Determinations for $r \times c$ Comparative Trials. <i>Biometrics</i> , 1977, 33, 315.	1.6	60
250	Heart Rate and Blood Pressure in Black Newborns and in White Newborns. <i>Pediatrics</i> , 1976, 58, 283-287.	4.5	12
251	Phasic Heart Rate Responses: Different Patterns in Black and in White Newborns. <i>Psychosomatic Medicine</i> , 1975, 37, 326-332.	2.2	4
252	On Stepwise Discriminant Analyses Applied to Physiologic Data. <i>Psychophysiology</i> , 1974, 11, 703-709.	2.6	32

#	ARTICLE	IF	CITATIONS
253	On a Stepwise Procedure for Two Population Bayes Decision Rules Using Discrete Variables. <i>Biometrics</i> , 1973, 29, 551.	1.6	9
254	Depression as a symptom of alcoholism: Search for a phenomenon.. <i>Journal of Abnormal Psychology</i> , 1968, 73, 195-197.	1.9	55
255	Title is missing!. , 0, .		1
256	Differences Between Glycemia Estimates from Hemoglobin A1c and Continuous Glucose Monitoring and Their Association with Complete Blood Counts. <i>Diabetes Technology and Therapeutics</i> , 0, , .	4.6	0
257	Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). <i>Diabetes Care</i> , 0, 49, 325-334.	6.2	0